Insider · CIK 0001557533
Jeffrey Robert Ajer
director
Files at NKTR (NEKTAR THERAPEUTICS), VRDN (Viridian Therapeutics, Inc.\DE). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | NKTR NEKTAR THERAPEUTICS | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 4,277 | 17 d ago |
| Sep 23, 2026 | NKTR NEKTAR THERAPEUTICS | AGrant or award Stock Optionderivative | +4,000 | $0.00 | $0 | 4,000 | 17 d ago |
| Sep 30, 2025 | NKTR NEKTAR THERAPEUTICS | AGrant or award Stock Optionderivative | +8,000 | $0.00 | $0 | 8,000 | Oct 1, 2025 |
| Jul 1, 2025 | VRDN Viridian Therapeutics, Inc.\DE | AGrant or award Stock Option (Right to Buy)derivative | +21,000 | $0.00 | $0 | 21,000 | Jul 2, 2025 |
| Apr 7, 2025 | VRDN Viridian Therapeutics, Inc.\DE | AGrant or award Stock Option (Right to Buy)derivative | +42,000 | $0.00 | $0 | 42,000 | Apr 9, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.